Welcome to the eighth issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter, you can download the latest issue [1].
All of our core studies have now completed their clinical phase and our work strand teams are busy analysing this data. We are working hard to get our knowledge management platform established as well as working with our partners to analyse our bio-banked samples. Some of our plans have been impacted by the COVID-19 pandemic but we are aiming to deliver more results in 2020. We hope to share the top-line data from the WS4 MEX and MAPLE studies with you via an on-line meeting on 27 August 2020.
Data from our biostratification study became available as 2019 ended. Although the data demonstrated that we had not met our primary endpoint for the Intention-to-Treat population, our pre-specified Per-Protocol analysis, which excluded potentially confounding data from participants who couldn’t (for one reason or another) follow the protocol, was positive and consistent with our pre-study assumptions. In addition, it was clear from further analysis of patients who could follow the protocol that those who reduced treatment according to biomarker directed therapy showed no evidence of clinical deterioration, despite being on lower corticosteroid doses.
Update reports are also provided on:
Our manuscript detailing with our primary findings of Work-strand 1 is currently being considered for publication in the Lancet Respiratory Medicine journal.
References
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
